



(12) Translation of
european patent specification

(11) NO/EP 2125698 B1

NORWAY

(19) NO
(51) Int Cl.
C07C 217/74 (2006.01)
C07B 59/00 (2006.01)
C07C 211/64 (2006.01)
C07C 215/64 (2006.01)
C07D 265/16 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.12.27
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.08.31
(86)	European Application Nr.	08732084.2
(86)	European Filing Date	2008.03.13
(87)	The European Application's Publication Date	2009.12.02
(30)	Priority	2007.03.15, US, 895049 P 2007.06.15, US, 944399 P
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
(73)	Proprietor	Auspex Pharmaceuticals, Inc., 3333 North Torrey Pine Court, Suite 400, La Jolla, CA 92037, US-USA
(72)	Inventor	GANT, Thomas, G., 1261 Liberty Way, Suite C, Vista, CA 92081-8356, US-USA SEPEHR, Sarshar, 1261 Liberty Way, Suite C, Vista, CA 92081-8356, US-USA WOO, Soon, Hyung, 1261 Liberty Way, Suite C, Vista, CA 92081-8356, US-USA
(74)	Agent or Attorney	Onsagers AS, Postboks 1813 Vika, 0123 OSLO, Norge


(54) Title **DEUTERATED d9-VENLAFAXINE**

(56) References
Cited:

WO-A-2007/064697
US-A1- 2007 149 622
B. R. DENT: "Certificate of Analysis Venlafaxine-d6 HCl"[Online] 26 April 2006 (2006-04-26), XP002489186
BDG Synthesis, Wellington, NZ Retrieved from the Internet:
URL:http://www.bdg.co.nz/uploads/tx_chem/C_OA_venlafaxine-d6.pdf> [retrieved on 2008-07-18]
B. R. DENT: "Certificate of Analysis O-Desmethylvenlafaxine-d6 HCl"[Online] 26 April 2006
(2006-04-26), XP002489187 BDG Synthesis, Wellington, NZ Retrieved from the Internet:
URL:http://www.bdg.co.nz/uploads/tx_chem/C_OA_Odesmethylvenlafaxine-d6.pdf> [retrieved on 2008-07-18]
BASAPPA KAVITHA C V ET AL: "Simple and an efficient method for the synthesis of 1-[2-dimethylamino-1-(4-methoxy-phenyl)-et hyl]-cyclohexanol hydrochloride: (+/-) venlafaxine racemic mixtures" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 14, no. 12, 21 June 2004 (2004-06-21), pages 3279-3281, XP004841389 ISSN: 0960-894X cited in the application
LIU ET AL: "Simultaneous stereoselective analysis of venlafaxine and O-desmethylvenlafaxine enantiomers in human plasma by HPLC-ESI/MS using a vancomycin chiral column" JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 850, no. 1-2, 30 November 2006 (2006-11-30), pages 183-189, XP022044059 ISSN: 1570-0232
FRANCOIS DESCHAMPS: "Catalog 2007-08" [Online] October 2007 (2007-10), SYNTHÈSE APTOCHEM, MONTRÉAL, CANADA, XP002490781 Retrieved from the Internet:
URL:<http://www.aptochem.com/Catalog.pdf>> [retrieved on 2008-07-17] page 44
FOSTER A B: "Deuterium isotope effects in the metabolism of drugs and xenobiotics: implications for drug design", ADVANCES IN DRUG RESEARCH, ACADEMIC PRESS, LONDON, GB, vol. 14, 1 January 1985 (1985-01-01), pages 1-40, XP009086953, ISSN: 0065-2490

PATENTKRAV

1. Polymorf av hydrokloridsaltet av d₉-1-[2-dimetylamino-1-(4-metoksyfenyl)-etyl]-sykloheksanolhydroklorid med strukturformelen:



5

hvor nevnte polymorf oppviser høyintensitets-diffraksjonstopper ved diffraksjonsvinkler (2θ) på 6,683, 10,201, 13,441, 15,517, 18,198, 19,719, 20,258, 21,68, 22,658, 25,543, 28,022 og 35,02 i røntgenpulverdiffraksjonsanalyse.

10 2. Polymorf ifølge krav 1, hvor polymorfen har et røntgendiffraksjonsspektrum som er vesentlig det samme som vist på figur 2.

15 3. Polymorf ifølge krav 1, hvor polymorfen har et røntgendiffraksjonsspektrum som har karakteristiske topper uttrykt i grader (2θ) ved omtrent:

2-theta	RI	2-theta	RI	2-theta	RI
6.683	15.5	22.658	24.8	31.379	8.2
10.201	93.6	23.923	2.7	31.978	9.1
13.441	27.8	25.322	9.6	32.28	10.5
15.014	7.6	25.543	22.4	32.701	6.5
15.517	66.2	26.502	6.7	32.981	2.3
16.458	1.5	27.122	9.5	34.12	9.1
16.84	10.3	27.557	5.5	35.02	33.4
17.206	2.7	28.022	20.9	36.024	3.1
18.198	41	28.64	4.4	36.842	2.6
19.719	34.1	29.241	10.6	37.5	6.7
20.258	100	29.659	7.1	38.341	3.9
21.68	71.2	31.079	11.9	38.753	1.2